BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 30203362)

  • 21. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adult epithelioid glioblastoma exhibits an extremely poor prognosis and high frequency of SWI/SNF complex mutation: Insights from a retrospective study.
    Xi S; Jiang S; Li H; Huang Q; Lu J; Zhang X; Li Z; Zeng J
    Int J Cancer; 2024 Jul; 155(1):172-183. PubMed ID: 38411299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular analysis of diffuse intrinsic brainstem gliomas in adults.
    Reyes-Botero G; Giry M; Mokhtari K; Labussière M; Idbaih A; Delattre JY; Laigle-Donadey F; Sanson M
    J Neurooncol; 2014 Jan; 116(2):405-11. PubMed ID: 24242757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker-driven diagnosis of diffuse gliomas.
    Appin CL; Brat DJ
    Mol Aspects Med; 2015 Nov; 45():87-96. PubMed ID: 26004297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.
    Rao S; Kanuri NN; Nimbalkar V; Arivazhagan A; Santosh V
    Neuropathology; 2019 Apr; 39(2):78-84. PubMed ID: 30937985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.
    Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M
    Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
    Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
    Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features.
    Olar A; Tran D; Mehta VP; Reinhardt A; Manekia JH; Garnovskaya M; Ellezam B; Luthra R; Sulman EP; Mohila CA; Campbell GA; Powell SZ; Fuller GN; Aldape KD; Adesina AM
    Clin Neuropathol; 2019; 38(2):59-73. PubMed ID: 30499772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation.
    Kanamori M; Suzuki H; Takei H; Sonoda Y; Uenohara H; Tominaga T
    Brain Tumor Pathol; 2016 Jan; 33(1):50-6. PubMed ID: 26404554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric low-grade gliomas can be molecularly stratified for risk.
    Yang RR; Aibaidula A; Wang WW; Chan AK; Shi ZF; Zhang ZY; Chan DTM; Poon WS; Liu XZ; Li WC; Zhang RQ; Li YX; Chung NY; Chen H; Wu J; Zhou L; Li KK; Ng HK
    Acta Neuropathol; 2018 Oct; 136(4):641-655. PubMed ID: 29948154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
    Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
    Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
    Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
    Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.